Higher baseline levels of IL-17 were associated with greater reductions in depression severity in response to combined bupropion-SSRI treatment but not SSRI monotherapy or the combination of venlafaxine and mirtazapine (Jha et al., 2017). Here, IL17A is linked to depressive disorder.